Adalimumab biosimilar - Fujifilm Kyowa Kirin Biologics

Drug Profile

Adalimumab biosimilar - Fujifilm Kyowa Kirin Biologics

Alternative Names: FKB-327

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator FUJIFILM Corporation - Kyowa Hakko Kirin (JV); Fujifilm Kyowa Kirin Biologics
  • Developer Fujifilm Kyowa Kirin Biologics
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 06 Mar 2017 Fujifilm Kyowa Kirin Biologics prepares to file application for marketing authorisation for adalimumab biosimilar
  • 03 Mar 2017 The UK High Court of Justice (Patents) Rules in Fujifilm Kyowa Kirin Biologics' favour against AbbVie Biotechnology on Rheumatoid arthritis, Psoriasis and Psoriatic arthritis dosing regimens for adalimumab as obvious and unpatentable
  • 18 Jul 2016 Fujifilm Kyowa Kirin Biologics completes a phase III trial for Rheumatoid arthritis in the US, Canada, Germany, Spain, Bulgaria, Chile, Czech Republic, Peru, Romania, Russia, Poland and Ukraine (NCT02260791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top